The short answer
Bitter melon has not been shown to cause extra hypoglycemia with insulin aspart in the reviewed evidence. Human findings vary, and a supplement should not replace the insulin plan.
What this answer covers
Momordica charantia oral capsule evidence; food, juice, seed and concentrated extracts differ.
- Supplement or preparation
- Momordica charantia
- Medication ingredient
- insulin aspart, human
The controlled trial was not clearly positive
A small placebo-controlled trial on standard diabetes therapy found no significant HbA1c or fasting-glucose benefit from bitter-melon capsules. This challenges the assumption that every preparation substantially lowers glucose.
The insulin identity was not established
The inspected abstract does not identify an insulin-aspart subgroup or a rate of hypoglycemia during aspart co-use. General diabetes treatment is not enough to establish a particular drug interaction.
Check preparation rather than relying on the name
The tested capsules do not represent all juices, foods or extracts. Different amounts and plant parts may produce different exposure; neither a negative trial nor traditional use establishes universal safety.
Review unexpected readings
Discuss the exact product and dose with the diabetes team before starting or stopping it. Follow your agreed glucose-monitoring and low-glucose treatment plan; do not adjust insulin on your own. Keep the labeled insulin meal instructions and do not use a supplement to substitute for insulin.
Evidence and practical considerations
Side effects & toxicity
Small indirect capsule trial was null for major glucose outcomes; no verified insulin-aspart co-use or hypoglycemia incidence.
- Exact scope
- Momordica charantia oral capsule evidence; food, juice, seed and concentrated extracts differ. with Insulin aspart human RxCUI51428 IN; NovoLog/Fiasp formulation and subcutaneous/pump/supervised intravenous routes distinguished.
- Medication form and route
- injected insulin aspart; oral supplement
What remains uncertain
- No source-specific uncertainty removed; no invented event rate or universal insulin adjustment.
Factors that may matter: Exact insulin product; Meal pattern; Dose; Other diabetes treatment; Kidney and liver function; Supplement preparation.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 2: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes receiving exact insulin-aspart product.
Hypoglycemia can be severe. Meal pattern, activity and added glucose-active agents affect risk. Niacin can decrease glucose-lowering effect. Mild hypoglycemia may be treated with oral glucose; severe episodes need emergency treatment.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Not premixed insulin or all insulin analogs. Product-specific timing and device instructions apply. Fiasp niacinamide excipient is not oral pharmacologic nicotinic acid. Label rates do not measure supplement interactions.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 40adults with type2diabetes.
No significant improvement in HbA1c or fasting glucose with bitter-melon capsules versus placebo on standard therapy.
How this applies: Exact insulin aspart formulation and route distinguished from other insulins, oral medicines and premixed products; supplement preparation and endpoint limits retained.
Small trial; abstract does not identify insulin-aspart exposure or establish an exact-pair hypoglycemia rate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact insulin-aspart article with product, route, botanical and clinical endpoint boundaries. | |
| Research summary published |
Article revision: 20a059b77ba7a65b
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.